Efficacy and tolerability of second-generation antidepressants in social anxiety disorder

International Clinical Psychopharmacology

Volumn 23, Issue 3, 2008, Pages 170-179

  Hansen, Richard A ^a   Gaynes, Bradley N ^b   Gartlehner, Gerald ^c   Moore, Charity G ^c   Tiwari, Ruchi ^d   Lohr, Kathleen N ^e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c DANUBE UNIVERSITY KREMS   (Austria)

^d OHIO STATE UNIVERSITY   (United States)

^e RTI INTERNATIONAL   (United States)

Author keywords

Indirect comparison; Network meta analysis; Second generation antidepressant; Social anxiety disorder; Social phobia

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ASTHENIA; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG TOLERABILITY; EJACULATION DISORDER; HUMAN; INSOMNIA; LIBIDO; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SWEATING; SYSTEMATIC REVIEW; XEROSTOMIA;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DISABILITY EVALUATION; EVIDENCE-BASED MEDICINE; HUMANS; PHOBIC DISORDERS; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 42149089864     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3282f4224a     Document Type: Review

References (55)

1. Allgulander C (1999). Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 100:193-198.
2. Allgulander C, Nilsson B (2001). A prospective study of 86 new patients with social anxiety disorder. Acta Psychiatr Scand 103:447-452.
3. Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, et al. (2004). Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 19:387-396.
4. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders-4th edition. Washington, DC: American Psychiatric Association.
5. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M (1999). Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 175:120-126.
6. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101.
7. Blanco C, Schneier FR, Schmidt A, Blanco-Jerez CR, Marshall RD, Sanchez-Lacay A, et al. (2003). Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety 18:29-40.
8. Blomhoff S, Haug TT, Hellstrom K, Holme I, Humble M, Madsbu HP, et al. (2001). Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 179:23-30.
9. Centre for Reviews and Dissemination (2001). Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD report No. 4. 2nd ed. York, United Kingdom: Centre for Reviews and Dissemination.
10. Davidson J, Yaryura-Tobias J, DuPont R, Stallings L, Barbato LM, van der Hoop RG, et al. (2004). Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24:118-125.
11. Davidson JR (2006). Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry 67 (Suppl 12):20-26.
12. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634.
13. Egger M, Smith GD, Altman DG (2001). Systematic reviews in health care. 2nd ed. London: BMJ.
14. Fedoroff IC, Taylor S (2001). Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol 21: 311-324.
15. Fehm L, Pelissolo A, Furmark T, Wittchen HU (2005). Size and burden of social phobia in Europe. Eur Neuropsychopharmacol 15:453-462.
16. Fox DM (2005). Evidence of evidence-based health policy: the politics of systematic reviews in coverage decisions. Health Aff (Millwood) 24:114-122.
17. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al. (2005). Indirect comparisons of competing interventions. Health Technol Assess 9:1-134, iii-iv.
18. Gould RA, Buckminister S, Pollack MH, Otto MW, Yap L (1997). Cognitive-behavioral and pharmacological treatments of social phobia: a meta-analysis. Clin Psychol Sci Pract 4:291-306.
19. Guy W (1976). ECDEU assessment manual for psychopharmacology. Revised DHEW pub. Rockville: (ADM), National Institutes of Mental Health.
20. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS (2005). Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 143:415-426.
21. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. (2001). Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 20:21-35.
22. Hedges DW, Brown BL, Shwalb DA, Godfrey K, Larcher AM (2007). The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol 21:102-111.
23. Hedges LV, Olkin I (1985). Statistical methods for meta-analysis. Orlando: Academic Press.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ 327:557-560.
25. Kasper S, Stein DJ, Loft H, Nil R (2005). Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186:222-226.
26. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC (1995). Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 152:1368-1371.
27. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19.
28. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627.
29. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ (2002). Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 22:257-262.
30. Lader M, Stender K, Burger V, Nil R (2004). Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 19:241-248.
31. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV (1997). Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 27:93-105.
32. Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L (2004). Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 65:222-229.
33. Liebowitz MR (1987). Social phobia. Mod Probl Pharmacopsychiatry 22: 141-173.
34. Liebowitz MR (2005). In Symposium presented at the 25th Annual Meeting of the Anxiety Disorders Association of America; Seattle, Washington.
35. Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, et al. (2003). Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 64: 785-792.
36. Liebowitz MR, Gelenberg AJ, Munjack D (2005). Venlafaxine extended release vs. placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 62:190-198.
37. Lumley T (2002). Network meta-analysis for indirect treatment comparisons. Stat Med 21:2313-2324.
38. Martins EA, Pigott TA, Bernstein SE, Doyle BB, Sunderland B, Smolka VM, et al. (1994). Sertraline in the treatment of patients with social phobia. Anxiety 1:291-297.
39. Muller JE, Koen L, Seedat S, Stein DJ (2005). Social anxiety disorder: current treatment recommendations. CNS Drugs 19:377-391.
40. Rickels K, Mangano R, Khan A (2004). A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 24:488-496.
41. Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, et al. (1994). Functional impairment in social phobia. J Clin Psychiatry 55: 322-331.
42. Stein DJ, Westenberg HG, Yang H, Li D, Barbato LM (2003). Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 6:317-323.
43. Stein DJ, Ipser JC, Balkom AJ (2004). Pharmacotherapy for social phobia. Cochrane Database Syst Rev.
44. Stein MB, Kean YM (2000). Disability and quality of life in social phobia: epidemiologic findings. Am J Psychiatry 157:1606-1613.
45. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I (1998). Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 280:708-713.
46. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B (1999). Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 156:756-760.
47. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM (2005). Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 177:280-288.
48. Van Ameringen M, Mancini C (2001). Pharmacotherapy of social anxiety disorder at the turn of the millennium. Psychiatr Clin North Am 24:783-803.
49. Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, et al. (2001). Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 158:275-281.
50. Van der Linden GJ, Stein DJ, van Balkom AJ (2000). The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 15 (Suppl 2):S15-S23.
51. Van Vliet IM, den Boer JA, Westenberg HG (1994). Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 115:128-134.
52. Versiani M (2000). A review of 19 double-blind placebo-controlled studies in social anxiety disorder (social phobia). World J Biol Psychiatry 1:27-33.
53. Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, et al. (2004). A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61:1153-1162.
54. Westenberg HG, Liebowitz MR (2004). Overview of panic and social anxiety disorders. J Clin Psychiatry 65 (Suppl 14):22-26.
55. Westenberg HG, Stein DJ, Yang H, Li D, Barbato LM (2004). A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24: 49-55.